超声引导下使用21G针经皮松解第一伸肌腱室治疗de Quervain病:35例前瞻性研究
本研究先在10例尸体腕上验证超声引导下21G针松解第一伸肌腱室支持带联合皮质类固醇注射的有效性,再前瞻性纳入35例de Quervain病患者进行临床研究;临床部分91.4%(32/35)在1个月内显著改善并避免手术,3例失败最终需手术;结论为该联合操作在现有实践中可行且并发症极少。
要点
- 超声引导下21G针松解联合皮质类固醇注射治疗de Quervain病在91.4%(32/35)病例中1个月内显著改善。
- 尸体研究显示所有腕关节松解均为「部分」松解,未发现并发症。
- 该操作仅需一次治疗、离岗3天,无医源性神经血管或肌腱损伤。
核心结论
- 超声引导下使用21G针行部分松解并同期皮质类固醇注射治疗de Quervain病在现有实践中可行,并发症极少。
研究设计与样本
- 研究分两部分:第一部分为10例尸体腕的操作后解剖分析;第二部分为35例前瞻性临床研究,结局通过6个月临床随访及研究结束时电话访谈评估。
关键影像表现/征象
- 尸体研究中未发现并发症,但所有腕关节的松解均确认为「部分」松解。
- 临床部分91.4%(32/35)在1个月内显著改善,结果稳定至研究结束,这些患者均避免了手术。
- 3例患者松解操作失败,最终需要手术治疗。
诊断标准与关键数值
- 疗效评估参数包括视觉模拟量表疼痛评分、QuickDASH和PRWE,并发放患者满意度问卷。
- 显著改善定义为临床部分91.4%(32/35)病例在1个月内达到改善。
临床应用与阅片要点
- 超声引导下21G针部分松解联合皮质类固醇注射可作为de Quervain病的可行治疗选择,并发症极少。
- 该操作仅需一次治疗,患者离岗3天。
- 操作中未发生医源性神经血管或肌腱损伤。
局限性
- 尸体研究中所有腕关节的松解均确认为「部分」松解。
- 临床部分3例患者松解操作失败并最终需要手术治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the efficacy of ultrasonography-guided percutaneous treatment of de Quervain tenosynovitis with the combination of a corticosteroid injection and release of the retinaculum of the first extensor compartment tendons with a 21-gauge needle.
MATERIALS AND METHODS: The first part of our study consisted of ten procedures on cadaver wrists followed by dissection to analyse the effectiveness of the retinaculum release and detect any collateral damage. The second part was a prospective clinical study of 35 procedures. Outcomes were evaluated through a 6-month clinical follow-up and telephone interview at the end of the study. The following parameters were monitored over time: pain level on a visual analogue scale, the QuickDASH and the PRWE. Patient satisfaction questionnaires were also administered.
RESULTS: No complications were found during the cadaver study. However, the release was confirmed as 'partial' in all wrists. In the clinical portion of this study, significant improvement was observed in 91.4 % of cases (32/35) within 1 month and the results were stable until the end of the study; all of these patients avoided surgery. The release procedure failed in three patients who eventually required surgical treatment.
CONCLUSION: US-guided partial release and simultaneous corticosteroid injection for treatment of de Quervain's disease using a 21-gauge needle is feasible in current practice, with minimal complications.
KEY POINTS: • Ultrasound-guided treatment of de Quervain's disease is feasible with a 21G needle. • There was notable regression of clinical signs in 91.4 % of cases. • The procedure is very safe, no iatrogenic neurovascular or tendinous injuries occurred. • Our procedure requires only one session and 3 days away from work.
引用
- Lapègue F, André A, Pasquier Bernachot E, et al. US-guided percutaneous release of the first extensor tendon compartment using a 21-gauge needle in de Quervain's disease: a prospective study of 35 cases. Eur Radiol. 2018. PMID: 29619521. doi:10.1007/s00330-018-5387-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。